Advertisement

Gout: Current Insights and Future Perspectives

Published:September 28, 2011DOI:https://doi.org/10.1016/j.jpain.2011.06.009

      Abstract

      Gout is a relatively common inflammatory arthritis that is typically known to occur in middle-aged men. The prevalence of gout appears to be shifting, however, and is increasing in the elderly population. Gout is characterized by severely intense pain and can greatly impact patient quality of life. The study of gout and associated conditions appears to have received research attention in the past, however there is a resurgence in gout interest due to the abundance of novel evidence surrounding its diagnosis, pathophysiology, and treatment. In this review we describe a general overview of gout including its assessment/diagnosis, clinical presentations, predisposing factors, pathophysiology, abortive and prophylactic therapy to control gouty inflammation, and the potential future direction of gout treatment.

      Perspective

      Gout is an underappreciated and extremely painful condition. Over the last 2 years new thought on pathophysiology of gout taking into account the inflammasome and new therapeutic agents have changed management strategies.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Agudelo C.A.
        • Weinberger A.
        • Schumacher H.R.
        • Turner R.
        • Molina J.
        Definitive diagnosis of gout by identification for urate crystals in asymptomatic metatarsophalangeal joints.
        Arthritis Rheum. 1979; 22: 559-560
        • Altman R.D.
        • Honig S.
        • Levin J.M.
        • Lightfoot R.W.
        Ketoprofen versus indomethacin in patients with acute gouty arthritis: A multicenter, double blind comparative study.
        J Rheumatol. 1988; 15: 1422-1426
      1. Anderson A, Singh JA: Pegloticase for chronic gout. Cochrane Database Syst Rev (3): CD008335, 2010

        • Baraf H.S.
        • Matsumoto A.K.
        • Maroli A.N.
        • Waltrip 2nd, R.W.
        Resolution of gouty tophi after twelve weeks of pegloticase treatment.
        Arthritis Rheum. 2008; 58: 3632-3634
        • Becker M.A.
        • Chohan S.
        We can make gout management more successful now.
        Curr Opin Rheumatol. 2008; 20: 167-172
        • Becker M.A.
        • Losman M.J.
        • Itkin P.
        • Simkin P.A.
        Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate.
        J Lab Clin Med. 1982; 99: 495-511
        • Becker M.A.
        • Schumacher H.R.
        • Benjamin K.L.
        • Gorevic P.
        • Greenwald M.
        • Fessel J.
        • Edwards L.
        • Kawata A.K.
        • Frank L.
        • Waltrip R.
        • Maroli A.
        • Huang B.
        • Sundy J.S.
        • Gout Natural History Study Group
        Quality of life and disability in patients with treatment-failure gout.
        J Rheumatol. 2009; 36: 1041-1048
        • Becker M.A.
        • Schumacher Jr., H.R.
        • Wortmann R.L.
        • MacDonald P.A.
        • Eustace D.
        • Palo W.A.
        • Streit J.
        • Joseph-Ridge N.
        Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
        N Engl J Med. 2005; 353: 2450-2461
        • Borstad G.C.
        • Bryant L.R.
        • Abel M.P.
        • Scroggie D.A.
        • Harris M.D.
        • Alloway J.A.
        Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.
        J Rheumatol. 2004; 31: 2429-2432
        • Brixner D.I.
        • Ho M.J.
        Clinical, humanistic, and economic outcomes of gout.
        Am J Manag Care. 2005; 11: S459-S464
        • Burns C.M.
        • Wortmann R.L.
        Gout therapeutics: New drugs for an old disease.
        Lancet. 2011; 377: 165-177
        • Cattermole G.N.
        • Man C.Y.
        • Cheng C.H.
        • Graham C.A.
        • Rainer T.H.
        Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis.
        Eur J Emerg Med. 2009; 16: 261-266
        • Chao J.
        • Terkeltaub R.
        A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
        Curr Rheumatol Rep. 2009; 11: 135-140
        • Cheng T.T.
        • Lai H.M.
        • Chiu C.K.
        • Chem Y.C.
        A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis.
        Clin Ther. 2004; 26: 399-406
        • Choi H.K.
        • Al-Arfaj A.
        • Nicolaou S.
        • Munk P.L.
        • Shojania K.
        • Reid G.
        • Nicolaou S.
        Dual energy computed tomography in tophaceous gout.
        Ann Rheum Dis. 2008; 68: 1609-1612
        • Choi H.K.
        • Atkinson K.
        • Karlson E.W.
        • Willett W.
        • Curhan G.
        Purine-rich foods, dairy and protein intake, and the risk of gout in men.
        N Engl J Med. 2004; 350: 1093-1103
        • Choi H.K.
        • Atkinson K.
        • Karlson E.W.
        • Willett W.
        • Curhan G.
        Alcohol intake and risk of incident gout in men: A prospective study.
        Lancet. 2004; 363: 1277-1281
        • Choi H.K.
        • Curhan G.
        Soft drinks, fructose consumption, and the risk of gout in men: Prospective cohort study.
        BMJ. 2008; 336: 309-312
        • Choi H.K.
        • Gao X.
        • Curhan G.
        Vitamin C intake and the risk of gout in men: A prospective study.
        Arch Intern Med. 2009; 169: 502-507
        • Choi H.K.
        • Mount D.B.
        • Reginato A.M.
        Pathogenesis of gout.
        Ann Intern Med. 2005; 143: 499-516
      2. Edwards N.L. Gout B. Klippel J.H. Clinical and Laboratory Features, in Primer on the Rheumatic Diseases. Springer, New York, NY, London, UK2007
        • Connor M.
        Allopurinol for pain relief: More than just crystal clearance?.
        Br J Pharmacol. 2009; 156: 4-6
        • Crawhall J.C.
        • Henderson J.F.
        • Kelley W.N.
        Diagnosis and treatment of the Lesch-Nyhan syndrome.
        Pediatr Res. 1972; 6: 504-513
        • Dahan K.
        • Fuchshuber A.
        • Adamis S.
        • Smaers M.
        • Kroiss S.
        • Loute G.
        • Cosyns J.P.
        • Hildebrandt F.
        • Verellen-Dumoulin C.
        • Pirson Y.
        Familial juvenile hyperuricemic nephropathy and autosomal dominant medullary cystic kidney disease type 2: Two facets of the same disease?.
        J Am Soc Nephrol. 2001; 12: 2348-2357
        • Day R.O.
        • Graham G.G.
        • Hicks M.
        • McLachlan A.J.
        • Stocker S.L.
        • Williams K.M.
        Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.
        Clin Pharmacokinet. 2007; 46: 623-644
        • De Ávila Fernandes E.
        • Kubota E.S.
        • Sandim G.B.
        • Miltraud S.A.
        • Ferrari A.J.
        • Fernandes A.R.
        Ultrasound features of tophi in chronic tophaceous gout.
        Skeletal Radiol. 2011; 40: 309-315
        • Dehghan A.
        • Köttgen A.
        • Yang Q.
        • Hwang S.J.
        • Kao W.L.
        • Rivadeneira F.
        • Boerwinkle E.
        • Levy D.
        • Hofman A.
        • Astor B.C.
        • Benjamin E.J.
        • van Duijn C.M.
        • Witteman J.C.
        • Coresh J.
        • Fox C.S.
        Association of three genetic loci with uric acid concentration and risk of gout: A genome-wide association study.
        Lancet. 2008; 372: 1953-1961
        • Edwards N.L.
        • Sundy J.S.
        • Forsythe A.
        • Blume S.
        • Pan F.
        • Becker M.A.
        Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy.
        J Med Econ. 2011; 14: 10-15
        • Ernst M.E.
        • Fravel M.A.
        Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
        Clin Ther. 2009; 31: 2503-2518
      3. Febuxostat (Uloric) for chronic treatment of gout.
        Med Lett Drugs Ther. 2009; 51: 37
        • Fernández C.
        • Noguera R.
        • González J.A.
        • Pascual E.
        Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide.
        J Rheumatol. 1999; 26: 2285-2286
        • Filippucci E.
        • Scirè C.A.
        • Delle Sedie A.
        • Iagnocco A.
        • Riente L.
        • Meenagh G.
        • Gutierrez M.
        • Bombardieri S.
        • Valesini G.
        • Montecucco C.
        • Grassi W.
        Ultrasound imaging for the rheumatologist. XXV. Sonographic assessment of the knee in patients with gout and calcium pyrophosphate deposition disease.
        Clin Exp Rheumatol. 2010; 28: 2-5
        • Finkelstein Y.
        • Aks S.E.
        • Hutson J.R.
        • Juurlink D.N.
        • Nguyen P.
        • Dubnov-Raz G.
        • Pollak U.
        • Koren G.
        • Bentur Y.
        Colchicine poisoning: The dark side of an ancient drug.
        Clin Toxicol (Phila). 2010; 48: 407-414
      4. Fitz-Patrick D, Drummond W, Pappas J, Hollister AS: Effects of a Purine Nucleoside Phosphorylase Inhibitor, BCX4208, on the Serum Uric Acid Concentrations in Patients with Gout. American College of Rheumatology Annual Meeting, Atlanta, Georgia; Abstract 150, November 2010

        • Gnanenthiran S.R.
        • Hassett G.M.
        • Gibson K.A.
        • McNeil H.P.
        Acute gout management during hospitalisation: A need for a protocol.
        Intern Med J. 2010 Jan 4; ([Epub ahead of print])
        • Goldbach-Mansky R.
        Blocking interleukin-1 in rheumatic diseases. Its initial disappointments and recent successes in the treatment of autoinflammatory diseases.
        Ann N Y Acad Sci. 2009; 1182: 111-123
        • Graser A.
        • Johnson T.R.
        • Bader M.
        • Staehler M.
        • Haseke N.
        • Nikolaou K.
        • Reiser M.F.
        • Stief C.G.
        • Becker C.R.
        Dual energy CT characterization of urinary calculi: Initial in vitro and clinical experience.
        Invest Radiol. 2008; 43: 112-119
        • Grassi W.
        • Meenagh G.
        • Pascual E.
        • Filippucci E.
        “Crystal clear”—sonographic assessment of gout and calcium pyrophosphate deposition disease.
        Semin Arthritis Rheum. 2006; 36: 197-202
        • Harrold L.R.
        • Andrade S.E.
        • Briesacher B.
        • Raebel M.A.
        • Fouayzi H.
        • Yood R.A.
        • Ockene I.S.
        The dynamics of chronic gout treatment: Medication gaps and return to therapy.
        Am J Med. 2010; 123: 54-59
        • Hoffman H.M.
        • Brydges S.D.
        The genetic and molecular basis of inflammasome-mediated disease.
        J Biol Chem. 2011 Feb 4; ([Epub ahead of print])
        • Hunter D.J.
        • York M.
        • Chaisson C.E.
        • Woods R.
        • Niu J.
        • Zhang Y.
        Recent diuretic use and the risk of recurrent gout attacks: The online case-crossover gout study.
        J Rheumatol. 2006; 33: 1341-1345
        • Jansen T.L.
        • Richette P.
        • Perez-Ruiz F.
        • Tausche A.K.
        • Guerne P.A.
        • Punzi L.
        • Leeb B.
        • Barskova V.
        • Uhlig T.
        • Pimentão J.
        • Zimmermann-Górska I.
        • Pascual E.
        • Bardin T.
        • Doherty M.
        International position paper on febuxostat.
        Clin Rheumatol. 2010 Apr 18; ([Epub ahead of print])
        • Janssens H.J.
        • Fransen J.
        • van de Lisdonk E.H.
        • van Riel P.L.
        • van Weel C.
        • Janssen M.
        A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis.
        Arch Intern Med. 2010; 170: 1120-1126
        • Janssens H.J.
        • Janssen M.
        • van de Lisdonk E.H.
        • Fransen J.
        • van Riel P.L.
        • van Weel C.
        Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care.
        Ann Rheum Dis. 2010; 69: 1255-1256
        • Janssens H.J.
        • Janssen M.
        • van de Lisdonk E.H.
        • van Riel P.L.
        • van Weel C.
        Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial.
        Lancet. 2008; 371: 1854-1860
      5. Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH: Systemic corticosteroids for acute gout. Cochrane Database Syst Rev (2): CD005521, 2008

        • Jarvis M.F.
        • Yu H.
        • McGaraughty S.
        • Wismer C.T.
        • Mikusa J.
        • Zhu C.
        • Chu K.
        • Kohlhaas K.
        • Cowart M.
        • Lee C.H.
        • Stewart A.O.
        • Cox B.F.
        • Polakowski J.
        • Kowaluk E.A.
        Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor.
        Pain. 2002; 96: 107-118
        • Kawenoki-Minc E.
        • Zieliński Z.
        Effect of balneotherapy in Ciechocinek Spa on the occurrence of gouty attacks and the symptoms of chronic gouty arthropathy (observations of 112 cures).
        Pol Med. 1972; J11: 1494-1500
        • Khanna P.P.
        • Perez-Ruiz F.
        • Maranian P.
        • Khanna D.
        Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: Short form-36 is responsive to change in chronic gout.
        Rheumatology (Oxford). 2011; 50: 740-745
        • Khanna D.
        • Sarkin A.J.
        • Khanna P.P.
        • Shieh M.M.
        • Kavanaugh A.F.
        • Terkeltaub R.A.
        • Lee S.J.
        • Singh J.A.
        • Hirsch J.D.
        Minimally important differences of the gout impact scale in a randomized controlled trial.
        Rheumatology (Oxford). 2011 Mar 3; ([Epub ahead of print])
        • Khosravan R.
        • Grabowski B.A.
        • Wu J.T.
        • Joseph-Ridge N.
        • Vernillet L.
        Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
        Clin Pharmacokinet. 2006; 45: 821-841
        • Ko K.H.
        • Hsu Y.C.
        • Lee H.S.
        • Lee C.H.
        • Huang G.S.
        Tophaceous gout of the knee: Revisiting MRI patterns in 30 patients.
        J Clin Rheumatol. 2010; 16: 209-214
        • Lawrence R.C.
        • Felson D.T.
        • Helmick C.G.
        • Arnold L.M.
        • Choi H.
        • Deyo R.A.
        • Gabriel S.
        • Hirsch R.
        • Hochberg M.C.
        • Hunder G.G.
        • Jordan J.M.
        • Katz J.N.
        • Kremers H.M.
        • Wolfe F.
        • National Arthritis Data Workgroup
        Estimates of the prevalence of arthritis and other rheumatic conditions in the United States.
        Part II. Arthritis Rheum. 2008; 58: 26-35
        • Liebman S.E.
        • Taylor J.G.
        • Bushinsky D.A.
        Uric acid nephrolithiasis.
        Curr Rheumatol Rep. 2007; 9: 251-257
        • Lin C.X.
        • Ma H.F.
        • Ma W.Z.
        • Zhou P.J.
        Clinical application of acupuncture and moxibustion to the treatment of gouty arthritis and analysis on their therapeutic effects.
        Zhen Ci Yan Jiu. 2009; 34: 67-69
        • Liu B.
        • Wang H.M.
        • Wang F.Y.
        Observation on therapeutic effect of electroacupuncture combined with local blocking therapy on acute gouty arthritis.
        Zhongguo Zhen Jiu. 2008; 28: 659-661
        • Maccagno A.
        • Di Giorgio E.
        • Romanowicz A.
        Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout.
        Curr Med Res Opin. 1991; 12: 423-429
        • Man C.Y.
        • Cheung I.T.
        • Cameron P.A.
        • Rainer T.H.
        Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: A double-blind, randomized, controlled trial.
        Ann Emerg Med. 2007; 49: 670-677
        • Mandell B.F.
        • Edwards N.L.
        • Sundy J.S.
        • Simkin P.A.
        • Pile J.C.
        Preventing and treating acute gout attacks across the clinical spectrum: A roundtable discussion.
        Cleve Clin J Med. 2010; 77: S2-S25
        • Martinon F.
        Signaling by ROS drives inflammasome activation.
        Eur J Immunol. 2010; 40: 616-619
      6. The Medical Letter on Drugs and Therapeutics. February 7, 53:9–12, 2011

        • Monu J.U.
        • Pope Jr., T.L.
        Gout: A clinical and radiologic review.
        Radiol Clin North Am. 2004; 42: 169-184
        • Nalbant S.
        • Chen L.X.
        • Sieck M.S.
        • Clayburne G.
        • Schumacher H.R.
        Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch.
        J Rheumatol. 2005; 32: 1762-1764
        • Neogi T.
        Clinical practice. Gout.
        N Engl J Med. 2011; 364: 443-452
        • Ning T.C.
        • Keenan R.T.
        Unusual clinical presentations of gout.
        Curr Opin Rheumatol. 2010; 22: 181-187
        • Niu Y.
        • Zhu H.
        • Liu J.
        • Fan H.
        • Sun L.
        • Lu W.
        • Liu X.
        • Li L.
        3,5,2′,4′-Tetrahydroxychalcone, a new non-purine xanthine oxidase inhibitor.
        Chem Biol Interact. 2011; 189: 161-166
        • Nuki G.
        • Simkin P.
        A concise history of gout and hyperuricemia and their treatment.
        Arthritis Res Ther. 2006; 8: S1
        • Ogdie A.
        • Hoch S.
        • Dunham J.
        • Von Feldt J.M.
        A roadmap for education to improve the quality of care in gout.
        Curr Opin Rheumatol. 2010; 22: 173-180
        • Pascual E.
        • Batlle-Gualda E.
        • Martinez A.
        • Rosas J.
        • Vela P.
        Synovial fluid analysis for diagnosis of intercritical gout.
        Ann Intern Med. 1999; 131: 756-759
        • Peláez-Ballestas I.
        • Hernández Cuevas C.
        • Burgos-Vargas R.
        • Hernández Roque L.
        • Terán L.
        • Espinoza J.
        • Esquivel-Valerio J.A.
        • Goycochea-Robles M.V.
        • Aceves F.J.
        • Bernard A.G.
        • Ventura L.
        • Shumsky C.
        • Hernández Garduño A.
        • Vázquez-Mellado J.
        Diagnosis of chronic gout: Evaluating the american college of rheumatology proposal, European league against rheumatism recommendations, and clinical judgment.
        J Rheumatol. 2010; 37: 1743-1748
        • Rezende-Lima W.
        • Parreira K.S.
        • García-González M.
        • Riveira E.
        • Banet J.F.
        • Lens X.M.
        Homozygosity for uromodulin disorders: FJHN and MCKD-type 2.
        Kidney Int. 2004; 66: 558-563
        • Richette P.
        • Bardin T.
        Gout.
        Lancet. 2010; 375: 318-328
        • Rott K.T.
        • Agudelo C.A.
        Gout.
        JAMA. 2003; 289: 2857-2860
        • Rubin B.R.
        • Burton R.
        • Navarra S.
        • Antigua J.
        • Londoño J.
        • Pryhuber K.G.
        • Lund M.
        • Chen E.
        • Najarian D.K.
        • Petruschke R.A.
        • Ozturk Z.E.
        • Geba G.P.
        Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial.
        Arthritis Rheum. 2004; 50: 598-606
        • Scalapino J.N.
        • Edwards W.D.
        • Steckelberg J.M.
        • Wooten R.S.
        • Callahan J.A.
        • Ginsburg W.W.
        Mitral stenosis associated with valvular tophi.
        Mayo Clin Proc. 1984; 59: 509-512
        • Schlesinger N.
        • Baker D.G.
        • Schumacher Jr., H.R.
        Serum urate during bouts of acute gouty arthritis.
        J Rheumatol. 1997; 24: 2256-2265
        • Schlesinger N.
        • Detry M.A.
        • Holland B.K.
        • Baker D.G.
        • Beutler A.M.
        • Rull M.
        • Hoffman B.I.
        • Schumacher Jr., H.R.
        Local ice therapy during bouts of acute gouty arthritis.
        J Rheumatol. 2002; 29: 331-334
        • Schlesinger N.
        Diagnosis of gout: Clinical, laboratory, and radiologic findings.
        Am J Manag Care. 2005; 11: S443-S450
        • Schlesinger N.
        • Yaspthan U.
        • Kirkpatrick P.
        Pegloticase.
        Nat Rev Drug Discov. 2011; 10: 17-18
        • Schmidt A.P.
        • Bohmer A.E.
        • Antunes C.
        • Schallenberger C.
        • Poriuncula L.O.
        • Elisabetsky E.
        • Lara D.R.
        • Souza D.O.
        Antinociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: Role of adenosine A1 receptors.
        Br J Pharmacol. 2009; 156: 163-172
      7. Schorn C, Frey B, Janko C, Schett G, Herrmann M: The NALP3 Inflammasome Is Activated by Sodium Overload and Water Influx in Gouty Arthritis. American College of Rheumatology Annual Meeting; Atlanta, Georgia; Abstract 2150, November 2010

        • Schumacher Jr., H.R.
        • Sieck M.S.
        • Rothfuss S.
        • Clayburne G.M.
        • Baumgarten D.F.
        • Mochan B.S.
        • Kant J.A.
        Reproducibility of synovial fluid analyses: A study among four laboratories.
        Arthritis Rheum. 1986; 29: 770-774
        • Schumacher H.R.
        • Boice J.A.
        • Daikh D.I.
        • Mukhopadhyay S.
        • Malmstrom K.
        • Ng J.
        • Tate G.A.
        • Molina J.
        Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.
        BMJ. 2002; 324: 1488-1492
        • Schumacher Jr., H.R.
        • Becker M.A.
        • Wortmann R.L.
        • MacDonald P.A.
        • Hunt B.
        • Streit J.
        • Lademacher C.
        • Joseph-Ridge N.
        Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial.
        Arthritis Rheum. 2008; 59: 1540-1548
      8. Schumacher HR, Berger M, Li-Yu J, Perez-Ruiz F, Burgos Vargas R, Li C: Efficacy and Tolerability of Celecoxib in the Treatment of Moderate to Extreme Pain Associated with Acute Gouty Arthritis: A Randomized Controlled Trial. American College of Rheumatology Annual Meeting; Atlanta, Georgia; Abstract 151, November 2010

        • Seegmiller J.E.
        • Dixon R.M.
        • Kemp G.J.
        • Angus P.W.
        • McAlindon T.E.
        • Dieppe P.
        • Rajagopalan B.
        • Radda G.K.
        Fructose-induced aberration of metabolism in familial gout identified by 31P magnetic resonance spectroscopy.
        Proc Natl Acad Sci U S A. 1990; 87: 8326-8330
        • Shrestha M.
        • Morgan D.L.
        • Moreden J.M.
        • Singh R.
        • Nelson M.
        • Hayes J.E.
        Randomized doubleblind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis.
        Ann Emerg Med. 1995; 26: 682-686
        • Singh D.
        • Huston K.K.
        IL-1 inhibition with anakinra in a patient with refractory gout.
        J Clin Rheumatol. 2009; 15: 366
        • Singh J.
        Quality of life and quality of care for patients with gout.
        Curr Rheumatol Rep. 2009; 11: 154-160
        • Singh J.
        • Hodges J.
        • Asch S.
        Opportunities for improving medication use and monitoring in gout.
        Ann Rheum Dis. 2009; 68: 1265-1270
        • So A.
        • De Smedt T.
        • Revaz S.
        • Tschopp J.
        A pilot study of IL-1 inhibition by anakinra in acute gout.
        Arthritis Res Ther. 2007; 9: R28
        • So A.
        • De Meulemeester M.
        • Pikhlak A.
        • Yücel A.E.
        • Richard D.
        • Murphy V.
        • Arulmani U.
        • Sallstig P.
        • Schlesinger N.
        Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.
        Arthritis Rheum. 2010; 62: 3064-3076
      9. So A, De Meulemeester M, Pikhlak A, Yücel1 AE, Arulmani U, Richard D, Stricker K, Ferreira A, Murphy V, Sallstig P, Schlesinger N: Rapid Improvement in Health-Related Quality of Life (HRQoL) in Gouty Arthritis Patients Treated with Canakinumab (ACZ885) Compared to Triamcinolone Acetonide. American College of Rheumatology Annual Meeting; Atlanta, Georgia; Abstract 1423, November 2010

        • Stehlik C.
        • Dorfleutner A.
        COPs and POPs: Modulators of inflammasome activity.
        J Immunol. 2007; 179: 7993-7998
        • Stocker S.L.
        • Williams K.M.
        • McLachlan A.J.
        • Graham G.G.
        • Day R.O.
        Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
        Clin Pharmacokinet. 2008; 47: 111-118
        • Stocker S.L.
        • Graham G.G.
        • McLachlan A.J.
        • Williams K.M.
        • Day R.O.
        Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
        J Rheumatol. 2011 Feb 1; ([Epub ahead of print])
        • Sundy J.S.
        • Ganson N.J.
        • Kelly S.J.
        • Scarlett E.L.
        • Rehrig C.D.
        • Huang W.
        • Hershfield M.S.
        Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
        Arthritis Rheum. 2007; 56: 1021-1028
        • Sundy J.S.
        Gout management: Let’s get it right this time.
        Arthritis Rheum. 2008; 59: 1535-1537
        • Sundy J.S.
        • Baraf H.S.
        • Becker M.A.
        • Edwards S.R.
        • Gutierrez-Urena S.R.
        • Treadwell E.L.
        • Vázquez-Mellado J.
        • Yood R.A.
        • Horowitz Z.
        • Huang W.
        • Maroli A.N.
        • Waltrip R.W.
        Efficacy and safety of intravenous (IV) pegloticase (PGL) in subjects with treatment failure gout (TFG): Phase 3 results from GOUT1 and GOUT2 [Abstract].
        Arthritis Rheum. 2008; 58: S400
        • Sundy J.S.
        • Becker M.A.
        • Baraf H.S.
        • Barkhuizen A.
        • Moreland L.W.
        • Huang W.
        • Waltrip 2nd, R.W.
        • Maroli A.N.
        • Horowitz Z.
        Pegloticase Phase 2 Study Investigators: Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study.
        Arthritis Rheum. 2008; 58: 2882-2891
        • Sutaria S.
        • Katbamna R.
        • Underwood M.
        Effectiveness of interventions for the treatment of acute and prevention of recurrent gout—a systematic review.
        Rheumatology (Oxford). 2006; 45: 1422-1431
        • Tassi S.
        • Carta S.
        • Delfino L.
        • Caorsi R.
        • Martini A.
        • Gattorno M.
        • Rubartelli A.
        Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion.
        Proc Natl Acad Sci U S A. 2010; 107: 9789-9794
        • Terkeltaub R.
        Learning how and when to employ uricase as bridge therapy in refractory gout.
        J Rheumatol. 2007; 34: 1955-1958
        • Terkeltaub R.A.
        Colchicine Update.
        Semin Arthritis Rheum. 2008; 38: 411-419
        • Terkeltaub R.
        • Sundy J.S.
        • Schumacher H.R.
        • Murphy F.
        • Bookbinder S.
        • Biedermann S.
        • Wu R.
        • Mellis S.
        • Radin A.
        The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.
        Ann Rheum Dis. 2009; 68: 1613-1617
        • Terkeltaub R.
        Update on gout: New therapeutic strategies and options.
        Nat Rev Rheumatol. 2010; 6: 30-38
        • Terkeltaub R.A.
        • Furst D.E.
        • Bennett K.
        • Kook K.A.
        • Crockett R.S.
        • Davis M.W.
        High vs low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.
        Arthritis Rheum. 2010; 62: 1060-1068
        • Tschopp J.
        • Schroder K.
        NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production.
        Nat Rev Immunol. 2010; 10: 210-215
      10. US Food and Drug Administration. FDA labeling information—Krystexxa (pegloticase). FDA website [online]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125293s0000lbl.pdf. Accessed August 11, 2011

      11. US FDA. Rheumatology information: Non-selective nonsteroidal anti-inflammatory drugs [online]. Available at: http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm106979.htm. Accessed July 2, 2010

        • Welch G.
        • Weinger K.
        • Barry M.J.
        Quality-of-life impact of lower urinary tract symptom severity: Results from the Health Professionals Follow-up Study.
        Urology. 2002; 59: 245-250
        • Wortmann R.L.
        • Macdonald P.A.
        • Hunt B.
        • Jackson R.L.
        Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials.
        Clin Ther. 2010; 32: 2386-2397
      12. Yang X, Dick R, Borges V, Yazdani N, Green A, Manhard K, Quart B, Yeh L: Evaluation of Drug-Drug Interaction Potential between RDEA594, Alloputinal and Febuxostat in Preclinical Species. ACR-ARHP Annual Scientific Meeting; Philadelphia, PA; Poster #1102, October 2009

        • Yang L.P.
        Oral colchicine (Colcrys): In the treatment and prophylaxis of gout.
        Drugs. 2010; 70: 1603-1613
      13. Yeh L, Hingorani V, Manhard K, Borges V, Nguyen M, Tieu K, Quart B: Safety and uric acid lowering effect in humans following multiple doses of RDEA806, a novel prodrug for the potential treatment of hyperuricemia. Annual European Congress of Rheumatology EULAR; Paris, France; Poster #THU0356, June 2008

      14. Yeh L, Kerr B, Shen Z, Hingorani V, Sheedy B, Nguyen M, Polvent L, Manhard K, Quart B: Safety, pharmacokinetics, and serum uric acid lowering effect of RDEA594, a novel uricosuric agent, in healthy volunteers. Annual European Congress of Rheumatology EULAR; Copenhagen, Denmark; Poster THU0451, June 2009

        • Zhang W.
        • Doherty M.
        • Bardin T.
        • Pascual E.
        • Barskova V.
        • Conaghan P.
        • Gerster J.
        • Jacobs J.
        • Leeb B.
        • Lioté F.
        • McCarthy G.
        • Netter P.
        • Nuki G.
        • Perez-Ruiz F.
        • Pignone A.
        • Pimentão J.
        • Punzi L.
        • Roddy E.
        • Uhlig T.
        • Zimmermann-Gòrska I.
        • EULAR Standing Committee for International Clinical Studies Including Therapeutics
        EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT).
        Ann Rheum Dis. 2006; 65: 1312-1324
        • Zhang Y.
        • Woods R.
        • Chaisson C.E.
        • Neogi T.
        • Niu J.
        • McAlindon T.E.
        • Hunter D.
        Alcohol consumption as a trigger of recurrent gout attacks.
        Am J Med. 2006; 119: 800.e13-800.e18